|
Patent landscape, scope, and claims: |
Executive summary
US Patent 5,914,322 is directed to a topical, transdermally penetrating, “systemic independent acting” formulation for skin and exposed-tissue diseases that combines (i) an anti-prostanglandin inhibitor drug (broadly including NSAIDs) with (ii) low-to-intermediate molecular weight hyaluronic acid (MW 150,000 to <750,000 Da) in a defined wt% range (about 1% to 3%) to facilitate transdermal penetration. The key claim scope turns on a tight MW window for HA, HA wt%, drug wt%, and the selection of covered disease indications. In the absence of the patent’s specification and prosecution history, the practical enforceability and competitive “design-around” landscape is best evaluated at the claim-parameter level: HA molecular weight, HA loading, drug loading, and whether a competitor can plausibly position its product outside those numeric ranges while still achieving penetration.
US Patent 5,914,322 landscape and claim scope for topical transdermal NSAID + hyaluronic acid (150,000–750,000 Da)
What does US 5,914,322 claim and what is the enforceable product format?
Core claimed format (Claim 1): a topical formulation that is “transdermally penetrating” and designed for “systemic independent acting” treatment of a disease/condition of skin and exposed tissue, where the disease is selected from a defined list, and the formulation includes:
- Drug: a “therapeutically effective non-toxic amount” of a drug that inhibits prostaglandin synthesis, delivered topically but intended to facilitate systemic action via transdermal penetration; drug wt%: about 1% to about 5% by weight.
- Carrier penetration excipient: a form of hyaluronic acid (HA) selected from hyaluronic acid and non-toxic salts, intended to facilitate skin/tissue penetration; HA MW: <750,000 Da and >150,000 Da; HA wt%: about 1% to about 3% by weight.
- Disease/indication coverage (Claim 1): expressly includes basal cell carcinoma, actinic keratoses, fungal lesions, “liver spots,” squamous cell tumours, metastatic breast cancer to the skin, primary and metastatic melanoma in the skin, genital warts, cervical cancer and HPV, plaque and nail psoriasis, corns on the feet, and hair loss on the head of pregnant women.
Secondary claim narrowing:
- Claim 2: drug is an NSAID.
- Claim 3: HA is sodium hyaluronate.
- Claim 4: NSAID limited to diclofenac, indomethacin, naproxen, or (±) tromethamine salt of ketorolac.
- Claim 5: NSAID limited to ibuprofen, piroxicam, propionic acid derivatives, acetylsalicylic acid, or flunixin.
How claim terms likely map to real-world product design
From a competitor’s perspective, the claim is not just “NSAID + hyaluronic acid.” Enforceability concentrates on four numeric/structural constraints:
- HA molecular weight window: >150,000 Da and <750,000 Da.
- HA loading window: 1% to 3% by weight.
- Drug loading window: 1% to 5% by weight.
- Drug class and specific candidates: prostaglandin synthesis inhibitor, with narrower dependent claim coverage for NSAIDs and specific NSAID identities.
Key built-in legal leverage
- The claims are composition-based and framed to specific quantitative HA and drug ranges. That typically makes validity and infringement hinge on assayable formulation parameters.
- The disease list is broad and includes oncology and HPV-related conditions. That can expand potential infringement theories but also increases potential prior-art risk and enablement scrutiny in litigated settings, depending on the specification content and evidentiary record.
How strong is the patent estate for US topical transdermal HA + prostaglandin inhibition?
Strength assessment from claim architecture alone (not from external citation mapping):
- Prosecution-style “tightness”: the HA MW and wt% ranges materially narrow scope. Narrower claim parameters can strengthen enforceability versus broad “HA of any MW” concepts.
- Dependent claim funneling: Claim 2-5 progressively narrow to NSAIDs and then specific NSAIDs. This creates multiple potential infringement hooks, but also creates multiple potential non-infringement positions: keep HA outside MW range, keep HA wt% outside 1–3%, keep drug wt% outside 1–5%, or choose a prostaglandin-inhibiting agent not captured by “NSAID” and the enumerated NSAIDs.
Likely litigation focal points
- HA molecular weight determination: competitors may use different HA grades (or blends) that can move the average MW outside the window.
- “Present in an amount between about” interpretation: wt% bands often become contested with analytical variance, manufacturing tolerances, and whether “about” expands the effective infringement band.
- “Transdermally penetrating” function: defendants often dispute whether their product is intended or actually functions as transdermally penetrating for systemic action. In composition claims, arguments can be directed to marketing language, labeling, formulation purpose, and comparative permeation data.
What is the scope of disease and indication coverage, and does it constrain infringement?
Claim 1 is explicit: the formulation must be “for the treatment of a disease or condition of the skin and exposed tissue,” where the disease is selected from the enumerated list. This means:
- A product marketed for an indication outside the list may attempt to avoid claim relevance by limiting “for treatment” use.
- However, if the product’s composition still falls within the claim and it is used for one of the listed indications, infringement theories can shift to use-based enforcement, even with composition claims, depending on jurisdictional posture and how “for treatment” is construed.
Indications listed in Claim 1 (verbatim categories)
- basal cell carcinoma
- actinic keratoses lesions (described as precancerous, often recurrent)
- fungal lesions
- “liver” spots
- lesions in the epidermis
- squamous cell tumours
- metastatic breast cancer to the skin
- primary and metastatic melanoma in the skin
- genital warts
- cervical cancer
- HPV
- psoriasis (plaque-type and nail bed psoriasis)
- corns on the feet
- hair loss on the head of pregnant women
What patents likely overlap with US 5,914,322, and where are the overlap zones?
Without the patent’s full bibliographic record, cited references, and prosecution file, an exact “all overlapping patents” map cannot be constructed here. What can be stated from claim scope is the overlap pattern typical for this technology cluster:
Overlap zone A: NSAID topical/transdermal systems
- Topical delivery of NSAIDs or prostaglandin synthesis inhibitors for skin and inflammatory conditions.
- Transdermal penetration systems using penetration enhancers or mucoadhesive matrices.
Overlap zone B: hyaluronic acid topical/transdermal penetration enhancers
- Formulations using HA to improve permeation, retention, hydration, wound healing, and drug delivery through skin.
- HA “molecular weight grade” distinctions (since Claim 1 requires MW >150,000 and <750,000 Da).
Overlap zone C: HA + anti-inflammatory/anti-prostaglandin actives
- Products combining HA with anti-inflammatory actives for dermatologic conditions.
- When HA MW is not restricted, prior art can be broader; when HA MW is restricted, novelty can shift to the grade window and the dose.
Overlap zone D: cancer/HPV topical claims using local drug delivery
- Topical or local treatments that target oncogenic lesions (basal cell carcinoma, squamous cell carcinoma, melanoma), or HPV-associated lesions and genital warts.
- These are likely to be the highest prior-art pressure areas because they are indication-expansive and time-dependent on established dermatology standards.
When does US 5,914,322 lose exclusivity in the US?
A complete exclusivity timeline requires patent term calculations using filing date, issue date, and any patent term adjustment or terminal disclaimer terms. Those data are not provided here.
What is determinable from the claim format alone:
- The patent is an issued US patent (US 5,914,322). It is subject to ordinary patent term from the relevant application filing date, with potential adjustments. Without the filing date and any PTA/terminal disclaimer details, an accurate expiration cannot be stated.
What Orange Book status applies to US 5,914,322 and can it block generic approval?
Orange Book eligibility applies to FDA-approved drug products that are listed as “patents” for the approved NDA/ANDA. The provided information does not include any FDA application association, NDA/ANDA numbers, or Orange Book listing details for US 5,914,322.
Accordingly, the Orange Book blocking effect cannot be determined from the claim text alone.
What generic entry risks exist for NSAID + hyaluronic acid topical transdermal products?
From the claim, a generic “entry risk” is defined by whether an entrant’s product falls within the numeric and structural bounds:
- HA molecular weight must fall within >150,000 and <750,000 Da.
- HA loading must fall within ~1% to 3% by weight.
- Drug loading must fall within ~1% to 5% by weight.
- Drug must inhibit prostaglandin synthesis, and if relying on dependent claim coverage, must be an NSAID and potentially an enumerated NSAID.
High-risk product profiles
- Topical/transdermal formulations using NSAIDs at 1–5% and HA at 1–3% with HA grade centered in the 150k–750k Da window.
Common design-around levers
- Use HA outside the MW window: <150,000 Da or ≥750,000 Da.
- Use HA outside 1–3% wt%.
- Use drug loading outside 1–5% wt%.
- Avoid NSAID identity if a strategy is to fall outside dependent claim ranges (note Claim 1 itself only requires prostaglandin synthesis inhibition, which can include non-NSAID prostaglandin inhibitors depending on claim construction).
How does US 5,914,322 compare with other HA-drug topical patents (claim parameter view)?
A practical competitive comparison in litigation or licensing typically reduces to:
- HA MW selection: 150k–750k vs broader or lower/higher MW HA.
- HA wt% range: 1–3% vs different dosing.
- Drug wt% range: 1–5% vs different dosing.
- Drug selection: NSAID enumerations vs broader inhibitors.
- Indication set: narrow dermatologic uses vs expansive oncology/HPV and pregnancy hair loss.
US 5,914,322 is distinctive because it combines quantified HA MW with quantified wt% and a wide indication list that includes oncology/HPV lesions.
What formulations are protected by the claims, and what exact combinations are covered?
Covered combinations, as framed by Claims 2–5 when those dependents are asserted, include:
NSAID families explicitly named (dependent coverage)
- Diclofenac
- Indomethacin
- Naproxen
- (±) tromethamine salt of ketorolac
- Ibuprofen
- Piroxicam
- Propionic acid derivatives
- Acetylsalicylic acid
- Flunixin
- plus Claim 2’s broader “NSAID” category if asserted without relying on enumerations in Claims 4–5.
HA form explicitly narrowed in dependent claim
- Sodium hyaluronate (Claim 3)
Quantitative formulation constraints (must be met for Claim 1)
- HA MW: >150,000 and <750,000 Da
- HA wt%: about 1% to 3%
- Drug wt%: about 1% to 5%
- Topical application intended to be transdermally penetrating
What patent litigation affects US 5,914,322?
No litigation dockets, parties, or court outcomes are included in the supplied information. Without those details, a litigation impact summary cannot be produced accurately.
How does a settlement or license typically work for HA-based topical transdermal NSAID products?
A typical licensing structure for this kind of composition claim focuses on:
- specific HA grades and concentration ranges
- specified drug actives and concentrations
- labeled indications corresponding to the claim’s disease list
- manufacturing control testing for HA MW distribution and assay of wt%
No specific settlement terms can be stated without deal documentation.
Regulatory pathway implications for products that would fall within the claims
Patent scope can affect regulatory strategy, but regulatory pathway facts (NDA vs ANDA vs 505(b)(2), labeling, and patent listing) are not supplied. Without FDA application metadata tied to US 5,914,322, regulatory consequences cannot be determined.
Commercial exposure: which product types would be most economically at risk?
Highest exposure is for topical or transdermal products that are positioned for:
- actinic keratoses or other precancerous lesions
- psoriasis (plaque and nail)
- genital warts / HPV-related lesions
- malignancy-adjacent dermatologic lesions (basal cell carcinoma, squamous cell carcinoma, melanoma)
combined with formulations meeting HA MW and wt% and NSAID/drug wt% constraints.
Lower exposure is for:
- cosmetic or wound-healing indications not in the claim list
- formulations using HA grades outside 150k–750k Da
- formulations outside 1–3% HA wt% or 1–5% drug wt%
Key Takeaways
- US 5,914,322 claims a topical, transdermally penetrating formulation combining a prostaglandin synthesis inhibitor (notably NSAIDs) with low-to-intermediate molecular weight hyaluronic acid (MW >150,000 and <750,000 Da).
- Infringement hinges on measurable numeric constraints: HA wt% (~1–3%), HA MW window, and drug wt% (~1–5%), plus the claimed disease/indication list.
- Dependent claims narrow to sodium hyaluronate and enumerated NSAIDs, creating multiple potential infringement or design-around paths.
- Exclusivity, Orange Book blocking effects, and litigation impacts cannot be determined from the provided claim text alone.
FAQs
- Can a competitor avoid infringement by using higher molecular weight hyaluronic acid (≥750,000 Da)?
- If a product uses NSAIDs but outside 1–5% wt%, does it avoid Claim 1 exposure?
- Does the claim cover any prostaglandin synthesis inhibitor, or only NSAIDs in practice?
- If a product falls within the composition claims, but is marketed for an indication not listed in Claim 1, how is infringement typically framed?
- If hyaluronic acid is blended from multiple molecular weight grades, how is the MW window likely assessed against the >150,000 and <750,000 Da limitation?
References
- US Patent 5,914,322 (provided claim text).
More… ↓
⤷ Start Trial
|
